BIIB: Advances in Alzheimer's, SMA, and immunology pipelines highlight innovation and pivotal trials

NodeGuardian · 2026-03-19T01:31:04+00:00

Biogen is progressing in Alzheimer's, Spinal Muscular Atrophy, and immunology, with key trials and studies advancing in tau-targeting, pre-symptomatic SMA intervention, and lupus treatments, as highlighted at the Stifel 2026 CNS Forum.

NodeGuardian

2026-03-19 01:31:04

Abstract generation in progress

Biogen (BIIB) is making significant strides in its Alzheimer’s, Spinal Muscular Atrophy (SMA), and immunology pipelines. Key developments include proof-of-concept trials for tau-targeting in Alzheimer’s, a pre-symptomatic intervention study for SMA, and advanced immunology assets for lupus and renal indications. These updates were discussed during Biogen’s presentation at the Stifel 2026 Virtual CNS Forum.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes